Drug makers face sweeping distribution overhaul
Apr 6, 2017
China launches a “Two-Invoice System” to simplify the drug distribution chain and reduce prices and corruption in the healthcare sector. The new policy may bring substantial compliance and business model challenges for pharmaceutical companies
The Chinese government has announced a new policy to fundamentally reduce marked-up prices and corruption in multi-tier distribution chains. The policy effectively requires, under most circumstances, at most only two invoices to be issued throughout the distribution chain, with one from the manufacturer to a distributor, and another from the distributor to the end hospital. Though this applies only to drugs, some provinces reportedly have been implementing similar policies for medical devices.
This premium content is reserved for
China Law & Practice Subscribers.
A Premium Subscription Provides:
- A database of over 3,000 essential documents including key PRC legislation translated into English
- A choice of newsletters to alert you to changes affecting your business including sector specific updates
- Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected].
